Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sirolimus-eluting versus uncoated stents in acute myocardial infarction.
Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carrié D, Slama MS, Merkely B, Erglis A, Margheri M, Varenne O, Cebrian A, Stoll HP, Snead DB, Bode C; TYPHOON Investigators. Spaulding C, et al. Among authors: cebrian a. N Engl J Med. 2006 Sep 14;355(11):1093-104. doi: 10.1056/NEJMoa062006. N Engl J Med. 2006. PMID: 16971716 Free article. Clinical Trial.
Cost effectiveness of sirolimus-eluting stents compared with bare metal stents in acute myocardial infarction: insights from the TYPHOON trial.
Canoui-Poitrine F, Jeanblanc G, Alberti C, Armoogum P, Cebrian A, Carrié D, Henry P, Teiger E, Slama M, Spaulding C, Durand-Zaleski I. Canoui-Poitrine F, et al. Among authors: cebrian a. Appl Health Econ Health Policy. 2009;7(1):19-29. doi: 10.1007/BF03256139. Appl Health Econ Health Policy. 2009. PMID: 19558192
Four-year follow-up of TYPHOON (trial to assess the use of the CYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with BallOON angioplasty).
Spaulding C, Teiger E, Commeau P, Varenne O, Bramucci E, Slama M, Beatt K, Tirouvanziam A, Polonski L, Stella PR, Clugston R, Fajadet J, de Boisgelin X, Bode C, Carrié D, Erglis A, Merkely B, Hosten S, Cebrian A, Wang P, Stoll HP, Henry P. Spaulding C, et al. Among authors: cebrian a. JACC Cardiovasc Interv. 2011 Jan;4(1):14-23. doi: 10.1016/j.jcin.2010.10.007. JACC Cardiovasc Interv. 2011. PMID: 21251624 Free article. Clinical Trial.
Impact of stent length on restenosis in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: analysis based on data from the Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON).
Rozenman Y, Witzling V, Tamari I, Turkisher V, Kriviski M, Bode C, Henry P, Teiger E, Cebrian A, Stoll HP, Spaulding C. Rozenman Y, et al. Among authors: cebrian a. EuroIntervention. 2009 Jun;5(2):219-23. doi: 10.4244/eijv5i2a34. EuroIntervention. 2009. PMID: 19527979 Clinical Trial.
Six-month results of the NEVO Res-Elution I (NEVO RES-I) trial: a randomized, multicenter comparison of the NEVO sirolimus-eluting coronary stent with the TAXUS Liberté paclitaxel-eluting stent in de novo native coronary artery lesions.
Ormiston JA, Abizaid A, Spertus J, Fajadet J, Mauri L, Schofer J, Verheye S, Dens J, Thuesen L, Dubois C, Hoffmann R, Wijns W, Fitzgerald PJ, Popma JJ, Macours N, Cebrian A, Stoll HP, Rogers C, Spaulding C; NEVO ResElution-I Investigators. Ormiston JA, et al. Among authors: cebrian a. Circ Cardiovasc Interv. 2010 Dec;3(6):556-64. doi: 10.1161/CIRCINTERVENTIONS.110.946426. Epub 2010 Nov 9. Circ Cardiovasc Interv. 2010. PMID: 21062998 Clinical Trial.
Correction: Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells.
Rio-Vilariño A, Cenigaonandia-Campillo A, García-Bautista A, Mateos-Gómez PA, Schlaepfer MI, Del Puerto-Nevado L, Aguilera O, García-García L, Galeano C, de Miguel I, Serrano-López J, Baños N, Fernández-Aceñero MJ, Lacal JC, Medico E, García-Foncillas J, Cebrián A. Rio-Vilariño A, et al. Among authors: cebrian a. Br J Cancer. 2024 May;130(8):1414. doi: 10.1038/s41416-024-02667-x. Br J Cancer. 2024. PMID: 38575733 Free PMC article. No abstract available.
Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells.
Rio-Vilariño A, Cenigaonandia-Campillo A, García-Bautista A, Mateos-Gómez PA, Schlaepfer MI, Del Puerto-Nevado L, Aguilera O, García-García L, Galeano C, de Miguel I, Serrano-López J, Baños N, Fernández-Aceñero MJ, Lacal JC, Medico E, García-Foncillas J, Cebrián A. Rio-Vilariño A, et al. Among authors: cebrian a. Br J Cancer. 2024 May;130(8):1402-1413. doi: 10.1038/s41416-024-02649-z. Epub 2024 Mar 11. Br J Cancer. 2024. PMID: 38467828 Free PMC article.
Vitamin-C-dependent downregulation of the citrate metabolism pathway potentiates pancreatic ductal adenocarcinoma growth arrest.
Cenigaonandia-Campillo A, Garcia-Bautista A, Rio-Vilariño A, Cebrian A, Del Puerto L, Pellicer JA, Gabaldón JA, Pérez-Sánchez H, Carmena-Bargueño M, Meroño C, Traba J, Fernandez-Aceñero MJ, Baños-Herraiz N, Mozas-Vivar L, Núñez-Delicado E, Garcia-Foncillas J, Aguilera Ó. Cenigaonandia-Campillo A, et al. Among authors: cebrian a. Mol Oncol. 2024 Feb 29. doi: 10.1002/1878-0261.13616. Online ahead of print. Mol Oncol. 2024. PMID: 38425123 Free article.
90 results